MX2012013383A - Composicion aceleradora de la produccion de adiponectina. - Google Patents
Composicion aceleradora de la produccion de adiponectina.Info
- Publication number
- MX2012013383A MX2012013383A MX2012013383A MX2012013383A MX2012013383A MX 2012013383 A MX2012013383 A MX 2012013383A MX 2012013383 A MX2012013383 A MX 2012013383A MX 2012013383 A MX2012013383 A MX 2012013383A MX 2012013383 A MX2012013383 A MX 2012013383A
- Authority
- MX
- Mexico
- Prior art keywords
- yeast
- extract
- preferable
- mass
- parts
- Prior art date
Links
- 102000011690 Adiponectin Human genes 0.000 title abstract 4
- 108010076365 Adiponectin Proteins 0.000 title abstract 4
- 239000000203 mixture Substances 0.000 title abstract 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 abstract 7
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 abstract 7
- 241000972773 Aulopiformes Species 0.000 abstract 4
- 235000019515 salmon Nutrition 0.000 abstract 4
- 229940041514 candida albicans extract Drugs 0.000 abstract 3
- 239000000284 extract Substances 0.000 abstract 3
- 229910052500 inorganic mineral Inorganic materials 0.000 abstract 3
- 239000011707 mineral Substances 0.000 abstract 3
- 239000012138 yeast extract Substances 0.000 abstract 3
- 241000271566 Aves Species 0.000 abstract 2
- 102000008186 Collagen Human genes 0.000 abstract 2
- 108010035532 Collagen Proteins 0.000 abstract 2
- 229920001436 collagen Polymers 0.000 abstract 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 abstract 1
- 102000004190 Enzymes Human genes 0.000 abstract 1
- 108090000790 Enzymes Proteins 0.000 abstract 1
- 102000015636 Oligopeptides Human genes 0.000 abstract 1
- 108010038807 Oligopeptides Proteins 0.000 abstract 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 abstract 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 abstract 1
- 229910052802 copper Inorganic materials 0.000 abstract 1
- 239000010949 copper Substances 0.000 abstract 1
- 239000011669 selenium Substances 0.000 abstract 1
- 229910052711 selenium Inorganic materials 0.000 abstract 1
- 230000001988 toxicity Effects 0.000 abstract 1
- 231100000419 toxicity Toxicity 0.000 abstract 1
- 239000011701 zinc Substances 0.000 abstract 1
- 229910052725 zinc Inorganic materials 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/34—Copper; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/60—Fish, e.g. seahorses; Fish eggs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/062—Ascomycota
- A61K36/064—Saccharomycetales, e.g. baker's yeast
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Marine Sciences & Fisheries (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Cardiology (AREA)
Abstract
Un problema a resolver es proporcionar una composición ingerible oralmente que promueva la producción de adiponectina y que esté libre de problemas de seguridad, como efectos secundarios y toxicidad; se prepara una composición promotora de la producción de adiponectina que comprende extracto de hueva de salmón, extracto de levadura de cerveza, colágeno aviar, y levadura que contiene mineral, y que tiene una actividad promotora de la producción de adiponectina; de preferencia el extracto de hueva de salmón comprende componentes con bajo peso molecular que se obtienen con la degradación enzimática de la hueva de salmón en oligonucleótidos y oligopéptidos; de preferencia el extracto de levadura de cerveza comprende de 50 a 80% de ARN; de preferencia la levadura mineral comprende, en levadura seca, de 2 a 3% de zinc, de 0.3 a 0.5% de cobre, y de 0.01 a 0.02% de selenio; de preferencia, la composición promotora de la producción de adiponectina comprende de 16 a 17 partes en masa del extracto de levadura de cerveza, de 33 a 34 partes en masa del colágeno aviar, y de 22 a 23 partes en masa de la levadura que contiene mineral por 100 partes en masa del extracto de hueva de salmón.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2010117264A JP4750213B1 (ja) | 2010-05-21 | 2010-05-21 | アディポネクチン産生促進組成物 |
| PCT/JP2011/002678 WO2011145307A1 (ja) | 2010-05-21 | 2011-05-13 | アディポネクチン産生促進組成物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2012013383A true MX2012013383A (es) | 2012-12-10 |
Family
ID=44597072
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2012013383A MX2012013383A (es) | 2010-05-21 | 2011-05-13 | Composicion aceleradora de la produccion de adiponectina. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US8883138B2 (es) |
| JP (1) | JP4750213B1 (es) |
| CN (1) | CN102892423B (es) |
| BR (1) | BR112012028054B1 (es) |
| CA (1) | CA2798556C (es) |
| MX (1) | MX2012013383A (es) |
| MY (1) | MY160509A (es) |
| RU (1) | RU2567053C2 (es) |
| TW (1) | TWI474829B (es) |
| WO (1) | WO2011145307A1 (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11478504B2 (en) | 2013-07-08 | 2022-10-25 | International Dehydrated Foods, Inc. | Compositions and methods for preventing/treating metabolic syndrome |
| CN106573034B (zh) * | 2014-07-31 | 2021-12-17 | 弗门尼舍有限公司 | 海洋肽和鱼核苷酸、组合物及其用于降低血糖的用途 |
| MX2020003102A (es) * | 2017-09-28 | 2020-07-28 | Int Dehydrated Foods Inc | Composiciones y metodos para prevenir/tratar el sindrome metabolico. |
| JP7428991B2 (ja) * | 2021-05-24 | 2024-02-07 | 国立大学法人北海道大学 | 糖の吸収抑制用剤 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3366769B2 (ja) * | 1995-03-03 | 2003-01-14 | 雪印乳業株式会社 | 白子を配合した栄養組成物 |
| JPH09224607A (ja) * | 1996-02-21 | 1997-09-02 | Soken:Kk | ダイエット補助食品 |
| JPH11290025A (ja) * | 1998-04-14 | 1999-10-26 | Towa Kk | 機能性加工食品 |
| JP3018186B1 (ja) | 1999-03-09 | 2000-03-13 | 大阪大学長 | 抗炎症剤、単球系細胞の増殖抑制剤 |
| CN1209978C (zh) * | 2000-08-30 | 2005-07-13 | 北京莱福赛茵生物工程技术有限公司 | 核酸补充营养保健食品及其制作方法 |
| CA2440144A1 (en) | 2001-03-14 | 2002-09-19 | Oklahoma Medical Research Foundation | Methods for reducing fat by administration of adiponectin |
| JP4547696B2 (ja) | 2001-06-07 | 2010-09-22 | 第一三共株式会社 | 肝硬変予防・治療剤 |
| US20040076690A1 (en) * | 2002-04-30 | 2004-04-22 | Kanebo, Ltd. | Compositions for weight loss with improved taste |
| JP2003339272A (ja) * | 2002-05-24 | 2003-12-02 | Japan Science & Technology Corp | アディポネクチン遺伝子欠損非ヒト動物 |
| JP2004016143A (ja) * | 2002-06-18 | 2004-01-22 | Ls Corporation:Kk | 水溶性核タンパク質分解物の製造方法 |
| JP2004201675A (ja) * | 2002-12-10 | 2004-07-22 | Arita Junichi | 糖尿病予防効果を有する亜鉛高含有食品 |
| JP2005232059A (ja) | 2004-02-18 | 2005-09-02 | Iichiro Shimomura | 低アディポネクチン血症予防・治療剤 |
| JP4634065B2 (ja) | 2004-05-14 | 2011-02-16 | 花王株式会社 | アディポネクチン低下抑制剤 |
| JP4834824B2 (ja) | 2004-07-08 | 2011-12-14 | 独立行政法人産業技術総合研究所 | アディポネクチン産生増強剤 |
| JP2006056836A (ja) | 2004-08-20 | 2006-03-02 | Taiyo Kagaku Co Ltd | 脂肪組織特異分泌蛋白産生増強組成物 |
| EP1908455A4 (en) * | 2005-06-13 | 2013-12-04 | Nissei Bio Co Ltd | HAIR CARE PREPARATION |
| JP2008063293A (ja) * | 2006-09-08 | 2008-03-21 | Yobo Igaku Shokuhin Kenkyusho Kk | アディポネクチン分泌促進剤、並びに該アディポネクチン分泌促進剤を含有する中性脂肪減少剤、抗肥満剤、飲食品添加剤及び機能性食品 |
| JP4728305B2 (ja) | 2007-09-04 | 2011-07-20 | 日本航空電子工業株式会社 | クリップ式検査治具およびそれに使用されるクリップ開状態保持機構 |
| JP2010037221A (ja) * | 2008-07-31 | 2010-02-18 | Hayashibara Biochem Lab Inc | アディポネクチン産生増強剤 |
| JP4738464B2 (ja) * | 2008-10-10 | 2011-08-03 | 武義 浦田 | アディポネクチン分泌促進用飲食品 |
-
2010
- 2010-05-21 JP JP2010117264A patent/JP4750213B1/ja active Active
-
2011
- 2011-05-13 BR BR112012028054-6A patent/BR112012028054B1/pt active IP Right Grant
- 2011-05-13 CA CA2798556A patent/CA2798556C/en active Active
- 2011-05-13 WO PCT/JP2011/002678 patent/WO2011145307A1/ja not_active Ceased
- 2011-05-13 CN CN201180024775.7A patent/CN102892423B/zh active Active
- 2011-05-13 MY MYPI2012700918A patent/MY160509A/en unknown
- 2011-05-13 MX MX2012013383A patent/MX2012013383A/es active IP Right Grant
- 2011-05-13 RU RU2012154820/15A patent/RU2567053C2/ru active
- 2011-05-13 US US13/261,517 patent/US8883138B2/en active Active
- 2011-05-20 TW TW100117843A patent/TWI474829B/zh active
Also Published As
| Publication number | Publication date |
|---|---|
| CA2798556C (en) | 2017-07-11 |
| US20130089532A1 (en) | 2013-04-11 |
| CN102892423B (zh) | 2014-12-03 |
| WO2011145307A1 (ja) | 2011-11-24 |
| TW201200148A (en) | 2012-01-01 |
| RU2012154820A (ru) | 2014-06-27 |
| BR112012028054B1 (pt) | 2020-11-17 |
| CN102892423A (zh) | 2013-01-23 |
| CA2798556A1 (en) | 2011-11-24 |
| MY160509A (en) | 2017-03-15 |
| TWI474829B (zh) | 2015-03-01 |
| RU2567053C2 (ru) | 2015-10-27 |
| JP4750213B1 (ja) | 2011-08-17 |
| US8883138B2 (en) | 2014-11-11 |
| JP2012121812A (ja) | 2012-06-28 |
| HK1176876A1 (en) | 2013-08-09 |
| BR112012028054A2 (pt) | 2016-08-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12018500713A1 (en) | Compositions and methods for inhibiting gene expression of lpa | |
| MX2017009532A (es) | Uso de acidos grasos de cadena corta en prevencion de cancer. | |
| PH12012500740A1 (en) | Nutritional compositions including a high protein component and exogenous nucleotides | |
| MY197418A (en) | Pharmaceutical composition for preventing or treating liver cancer, comprising tetraarsenic hexoxide crystalline polymorph | |
| MX2010012270A (es) | Inhibidores de dpp-iv para uso en el tratamiento de enfermedad hepatica grasa no alcoholica. | |
| WO2013003112A9 (en) | Methods and compositions for treatment of cancer and autoimmune disease | |
| EA201171435A1 (ru) | Твердые фармацевтические композиции и способы их получения | |
| MX2010003013A (es) | Inhibicion de angiogenesis. | |
| NZ630598A (en) | Method of engrafting cells from solid tissues | |
| IN2012DN02624A (es) | ||
| PH12019501293A1 (en) | Nutritional compositions containing butyrate and uses thereof | |
| MX2017014641A (es) | Composiciones y metodos para inhibir la expresion del gen de factor inducible por hipoxia alfa (hif2alfa). | |
| MX2012001306A (es) | Inhibicion de matastasis de tumor. | |
| PH12017501003A1 (en) | Aminoacid-based composition for fibroelastin recovery in dermal connective tissues | |
| MX2012013383A (es) | Composicion aceleradora de la produccion de adiponectina. | |
| SG10201909412RA (en) | Composition for suppressing muscular fatty change | |
| WO2008092099A8 (en) | Compositions and methods for treating hematopoietic malignancies | |
| MX2011011860A (es) | Composicion estimulante inmune que comprende un extracto de aronia sp. en combinacion con selenio y/o zinc. | |
| MX2020007779A (es) | Composiciones y métodos para tratar la cavidad bucal. | |
| NZ595440A (en) | Tumor suppression using human placenta-derived intermediate natural killer cells and immunomodulatory compounds | |
| BR112012016054A2 (pt) | Composições nutricionais compreendendo flocos de fruta incluindo ácido docosa-hexaenoico | |
| IN2012DN01878A (es) | ||
| EP2597949A4 (en) | SUBMIKROMETERZUSAMMENSETZUNGEN | |
| WO2010114185A1 (ko) | 암 특이 면역반응 유도능을 갖는 수지상 세포의 제조 방법, 이 수지상 세포를 포함하는 암의 예방, 치료, 또는 전이 억제용 약제학적 조성물 및 키트 | |
| NZ723206A (en) | A method of improving liver function |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |